CrossrefInfokarte
A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018)
European Journal of Cancer · 2026-11 · 248 · 117063
DOI: 10.1016/j.ejca.2026.117063 ↗Abstract
Kein Abstract verfügbar.
EUVIMED